Method of treating hemorrhagic shock or systemic inflammatory response syndrome
AssigneeWyeth
InventorsHeather A. Harris, Ruth A. Henderson
Life of this patent
Estimating the term…
Abstract
This invention provides the a method of treating or inhibiting hemorrhagic shock or systemic inflammatory response syndrome using an ERβ selective ligand.
Claims19
A method of treating or inhibiting hemorrhagic shock in a mammal in need thereof, which comprises providing to said mammal an effective amount of a non-uterotropic, non-mammotrophic ERβ selective ligand.
A method of treating or inhibiting systemic inflammatory response syndrome in a mammal in need thereof, which comprises providing to said mammal an effective amount of a non-uterotropic, non-mammotrophic ERβ selective ligand.
A method of treating or inhibiting organ damage or failure resulting from hemorrhagic shock or systemic inflammatory response syndrome in a mammal in need thereof, which comprises providing to said mammal an effective amount of a non-uterotropic, non-mammotrophic ERβ selective ligand.
A method of treating or inhibiting tissue damage following hypoperfusion in a mammal with low blood volume, which comprises providing to said mammal an effective amount of a non-uterotropic, non-mammotrophic ERβ selective ligand.
A method of inhibiting an increase in intestinal permiability following traumatic injury in a mammal in need thereof, which comprises providing to said mammal an effective amount of a non-uterotropic, non-mammotrophic ERβ selective ligand.
Dependencies are inferred from the claim text.